Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.

by Gregory Y H Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak
Published 2018-01-01

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensi...

by Xiaoyan Li, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y H Lip, Steve Deitelzweig
Published 2018-01-01

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.

by Alpesh Amin, Alessandra B Garcia Reeves, Xiaoyan Li, Amol Dhamane, Xuemei Luo, Manuela Di Fusco, Anagha Nadkarni, Keith Friend, Lisa Rosenblatt, Jack Mardekian, Xianying Pan, Huseyin Yuce, Allison Keshishian
Published 2019-01-01

Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study

by Steve Deitelzweig, Allison Keshishian, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Xiaoyan Li, Neeraja Balachander, Lisa Rosenblatt, Jack Mardekian, Xianying Pan, Manuela Di Fusco, Alessandra B. Garcia Reeves, Huseyin Yuce, Gregory Y. H. Lip
Published 2020-05-01